Neuren Pharmaceuticals (ASX:NEU) US$35m EU trigger puts royalties back in focus

Positive CHMP opinion could unlock first Rett therapy in Europe

Neuren Pharmaceuticals (ASX:NEU) has moved quickly from a European setback to a potential approval pathway in just a few months.

The company’s partner, Acadia Pharmaceuticals, has received a positive opinion from the Committee for Medicinal Products for Human Use for DAYBU, following a re examination procedure. CHMP is the European Medicines Agency committee that reviews human medicines and recommends whether the European Commission should approve them.

If the European Commission grants marketing authorisation, DAYBU would become the first treatment approved in the EU for neurobehavioral symptoms of Rett syndrome in patients aged 5 years and older. Rett syndrome is a rare neurological disorder that affects development, communication and movement, and often requires lifelong care.

For Neuren, the market should focus on the structure of the economics. Approval and launch would trigger US$35 million after first commercial sale in Europe, with royalties and future sales milestones sitting behind it.

Why the CHMP Reversal Matters More Than the Cheque

The immediate payment matters, but the bigger point is regulatory validation after a difficult review process.

Earlier this year, the European pathway looked less certain after Acadia pursued a re examination. The positive CHMP opinion now changes the tone of the debate because the asset has moved back toward a credible commercial path in Europe.

That does not mean approval is automatic. The European Commission still needs to make the final decision in the coming months, so investors should treat this as a major step forward rather than a completed launch event.

Europe Adds a Royalty Layer Without Neuren Funding the Launch

Neuren has licensed trofinetide globally to Acadia, which means Acadia carries the commercialisation work while Neuren keeps economic exposure.

In Europe, Neuren is entitled to US$35 million following first commercial sale, potential sales milestones of up to US$170 million and tiered royalties from the mid teens to low 20s % of net sales.

That structure is attractive for a company of Neuren’s size because it creates leverage to sales without forcing Neuren to build a full European sales force.

The key variable is launch quality. If Acadia can convert the first approved EU Rett therapy into meaningful adoption, Neuren gains a higher quality royalty stream that could help smooth the earnings profile over time.

The Next Rerate Still Depends on More Than DAYBU

DAYBU remains the commercial anchor, but Neuren’s second drug candidate, NNZ 2591, is still the more important pipeline option for long term upside.

NNZ 2591 is in development across multiple neurodevelopmental disorders, including Phelan McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Each of these conditions has limited approved treatment options, which is why orphan drug and fast track designations are important.

Neuren is currently running the Koala Phase 3 trial in children with Phelan McDermid syndrome. A Phase 3 trial is a late stage study designed to test whether a treatment works well enough and safely enough to support regulatory approval.

This means the investment case is now becoming two layered. DAYBU can provide near term regulatory and royalty momentum, while NNZ 2591 carries the next major clinical catalyst.

The Investors Takeaway for Neuren

The investor takeaway is that Neuren has regained momentum in Europe, but the stock still needs the final European Commission decision before investors can treat the EU opportunity as fully de risked.

If approval lands, the first commercial sale would trigger a US$35 million payment and open a royalty stream across a large regulated market. That would strengthen Neuren’s cash position and add another external validation point to the trofinetide platform.

The risk is timing and launch execution. Rare disease therapies can take time to build awareness, reimbursement coverage and physician adoption, even when the unmet need is clear.

From here, investors should watch three things. The European Commission decision, Acadia’s launch plan in Europe and progress from the Koala Phase 3 trial.

If those pieces line up, Neuren could move from being viewed mainly as a one product royalty story to a broader neurological drug platform with multiple valuation drivers. Investors can find more coverage of ASX listed biotech names and other growth stocks here at Stocks Down Under.